Vericel Corporation (NASDAQ: VCEL - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven analysts that are currently covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price

Frontier Capital Management Co. LLC increased its holdings in Vericel Corporation (NASDAQ: VCEL) by 74.3% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 398,960 shares of the biotechnology company's stock after buying an additional 170,006 shares during the period. Frontier Capital

Vericel Corporation (NASDAQ: VCEL - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven analysts that are presently covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year target price among

CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will participate in a fireside chat at the Stephens Annual Investment Conference at 11:00 a.m. ET (10:00 a.m. CT) on Thursday, November 20, 2025.

The average of price targets set by Wall Street analysts indicates a potential upside of 39.4% in Vericel (VCEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Vericel Corporation ( VCEL ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Eric Burns - Vice President of Finance & Investor Relations Dominick C. Colangelo - CEO, President & Director Joseph Mara - CFO & Treasurer Conference Call Participants Joshua Jennings - TD Cowen, Research Division Richard Newitter - Truist Securities, Inc., Research Division Ryan Zimmerman - BTIG, LLC, Research Division Caitlin Roberts - Canaccord Genuity Corp., Research Division Michael Kratky - Leerink Partners LLC, Research Division Jeffrey Cohen - Ladenburg Thalmann & Co. Inc., Research Division Presentation Operator Good day, and welcome to the Vericel Corporation Third Quarter 2025 Earnings Call.

Baltimore-based Brown Capital Management sold 861,020 shares of Vericel Corporation in the third quarter for an estimated $31 million. The transaction value represented 1.3% of Brown Capital's 13F reportable AUM as of quarter-end.

Vericel Corporation (VCEL) came out with quarterly earnings of $0.1 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.02 per share a year ago.

Record Third Quarter Total Revenue of $67.5 Million MACI Revenue Growth of 25% to $55.7 Million Net Income of $5.1 Million and Adjusted EBITDA Margin of 25% Record Third Quarter Operating Cash Flow of $22.1 Million More than 800 MACI Arthro Surgeons Trained to Date Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the third quarter ended September 30, 2025.

CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will participate in a fireside chat at the Wells Fargo Healthcare Conference at 3:45 p.m. ET on Thursday, September 4, 2025.